Rituxan - Rituximab - Dosage - Side Effects - Interactions - Warnings
Rituxan (Rituximab, MabThera) drug information, dosage, side effects, drug interactions, and warnings. Rituxan, generic drug name rituximab, also known as Mabthera, was first a cancer agent. Rituxan has been approved to be used along with the drug methotrexate to treat rheumatoid arthritis. Rituxan is being studied for conditions such as lupus, lupus nephritis, and vasculitis.
Subsequent Rituxan Treatment Yields Better Outcomes
11/16/2006, Subsequent Rituxan (rituximab) treatment in patients with rheumatoid arthritis who had an inadequate response to previous treatment with one or more anti-TNF drugs (Enbrel, Remicade, or Humira) produced a better outcome in a higher number of patients than with their first course of Rituxan treatment.
11/16/2006, Subsequent Rituxan (rituximab) treatment in patients with rheumatoid arthritis who had an inadequate response to previous treatment with one or more anti-TNF drugs (Enbrel, Remicade, or Humira) produced a better outcome in a higher number of patients than with their first course of Rituxan treatment.
Rituxan Approved For Rheumatoid Arthritis - The Facts Of Rituxan
03/01/2006, Rituxan, the world's best-selling cancer drug, has been FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).
03/01/2006, Rituxan, the world's best-selling cancer drug, has been FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).
Drug Monograph: Rituxan / Rituximab / MabThera
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody. It is the first monoclonal antibody to be used as a chemotherapeutic agent. Rituximab has been approved in Europe under the trade name "MabThera." Other ant-CD20 antibodies are under investigation. Rituximab is given as an intravenous infusion.
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody. It is the first monoclonal antibody to be used as a chemotherapeutic agent. Rituximab has been approved in Europe under the trade name "MabThera." Other ant-CD20 antibodies are under investigation. Rituximab is given as an intravenous infusion.
Patient Education: Rituxan / Rituximab Injections
Patient education for Rituxan / rituximab injections. Rituxan is currently used to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL). Rituxan may be given as a single medicine or as part of a regimen containing chemotherapy.
Patient education for Rituxan / rituximab injections. Rituxan is currently used to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL). Rituxan may be given as a single medicine or as part of a regimen containing chemotherapy.
Product Photographs: Rituxan / Rituximab
Product photographs of Rituxan / rituximab.
Product photographs of Rituxan / rituximab.
Monoclonal Antibody - What Is A Monoclonal Antibody?
Some of the newest biologic treatments for rheumatoid arthritis are monoclonal antibodies. What is a monoclonal antibody?
Some of the newest biologic treatments for rheumatoid arthritis are monoclonal antibodies. What is a monoclonal antibody?
Biologic Drugs - Are Some Arthritis Patients Unsuitable Candidates For Biologic Drugs?
The medical history of some arthritis patients make them unsuitable candidates for biologic drugs such as Enbrel, Remicade, Humira, Orencia, and Rituxan.
The medical history of some arthritis patients make them unsuitable candidates for biologic drugs such as Enbrel, Remicade, Humira, Orencia, and Rituxan.
10/31/2005 Rituxan History: Rituxan Granted Priority Review By FDA
10/31/2005, Rituxan (rituximab) has been granted "priority" review status by the U.S. Food and Drug Administration as a treatment for rheumatoid arthritis.
10/31/2005, Rituxan (rituximab) has been granted "priority" review status by the U.S. Food and Drug Administration as a treatment for rheumatoid arthritis.
04/07/2005 Rituxan History: Phase III Study For Rituxan Meets Endpoint
04/07/2005, The Phase III study of Rituxan for the treatment of rheumatoid arthritis has demonstrated that more study participants treated with Rituxan achieved ACR20 (20% improvement in symptoms) at week 24 compared to placebo.
04/07/2005, The Phase III study of Rituxan for the treatment of rheumatoid arthritis has demonstrated that more study participants treated with Rituxan achieved ACR20 (20% improvement in symptoms) at week 24 compared to placebo.
06/17/2004 Rituxan History: Rituxan Promising For Rheumatoid Arthritis
06/17/2004, Rituxan, a drug used to target B-cells, is showing promise as a treatment for rheumatoid arthritis.
06/17/2004, Rituxan, a drug used to target B-cells, is showing promise as a treatment for rheumatoid arthritis.
10/26/2003 Rituxan History: Rituxan Shows Benefit In Phase II Trials
10/26/2003, A single, short course of treatment with Rituxan (two infusions during the first 15 days of treatment) alone, or in combination with methotrexate or cyclophosphamide improved symptoms in patients with moderate to severe rheumatoid arthritis for up to 48 weeks, compared to methotrexate alone.
10/26/2003, A single, short course of treatment with Rituxan (two infusions during the first 15 days of treatment) alone, or in combination with methotrexate or cyclophosphamide improved symptoms in patients with moderate to severe rheumatoid arthritis for up to 48 weeks, compared to methotrexate alone.
06/01/2001 Rituxan History: B-Cell: Is Progress Being Made?
06/01/2001, News of exciting research developments and a potential cure for rheumatoid arthritis was splashed everywhere last November. There has been an eerie silence about it ever since. Professor Jonathan CW Edwards lets us know where things stand.
06/01/2001, News of exciting research developments and a potential cure for rheumatoid arthritis was splashed everywhere last November. There has been an eerie silence about it ever since. Professor Jonathan CW Edwards lets us know where things stand.
11/20/2000 Rituxan History: B-Cell Depletion Wading Through The Hype
11/20/2000, Were the recent reports which hyped B-lymphocyte depletion therapy as a potential cure for rheumatoid arthritis accurate or were the reports irresponsible journalism?
11/20/2000, Were the recent reports which hyped B-lymphocyte depletion therapy as a potential cure for rheumatoid arthritis accurate or were the reports irresponsible journalism?
11/01/2000 Rituxan History: B-Cell Depletion Triggers RA Remission
11/01/2000, Researchers from University College in London have presented findings from an experimental new rheumatoid arthritis treatment which involves B-lymphocyte depletion. Some say it's a "cure", others say a "remission", but everyone agrees it's exciting.
11/01/2000, Researchers from University College in London have presented findings from an experimental new rheumatoid arthritis treatment which involves B-lymphocyte depletion. Some say it's a "cure", others say a "remission", but everyone agrees it's exciting.
Rituxan: Development Status / Additional Clinical Trial Information
Development status and additional clinical trial information for Rituxan, from Genentech.
Development status and additional clinical trial information for Rituxan, from Genentech.